Eglen is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Eglen was first synthesized by Janssen Pharmaceutica in 1955.
It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.
Eglen could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.

Eglen - Pharmacology:

Binds to the Histamine H1 receptor and to muscarinic acetylcholine receptors. Eglen also inhibits contractions of vascular smooth muscle cells by blocking L type calcium channels. Eglen has also been implicated in binding to dopamine D2 receptors.

Generic name, Overdose, Half Life Eglen, Food Interactions, Chemical, etc..

Eglen see also

Chemical structure:
N N H H H H H H H H H H H H H H H H H H H H H H H H H H H H C26H28N2 2D chemical structure C26H28N2 SVG | 2D structure Cinnarizine chemical names, chemical properties, classification C26H28N2